欧洲泌尿外科学会上尿路尿路上皮癌指南:2020更新
欧洲泌尿外科学会(EAU)上尿路尿路上皮癌(UTUC)指南小组基于系统检索Medline及现有指南,制定了2020版UTUC管理指南。推荐采用2017年TNM分类,并针对诊断、风险分层、根治性与保留性治疗及预后因素给出推荐;强调低风险肿瘤且双肾功能良好者可首选保肾治疗,根治性肾输尿管切除术后膀胱内单次灌注丝裂霉素可降低膀胱肿瘤复发风险,局部晚期UTUC术后推荐顺铂为基础的化疗。
要点
- 推荐采用2017年TNM分类对UTUC进行分期。
- 低风险肿瘤且双肾功能良好者,保肾管理应作为首选治疗选择。
- 根治性肾输尿管切除术后,膀胱内单次灌注丝裂霉素可降低膀胱肿瘤复发风险。
核心结论
- UTUC罕见,数据不足以提供强推荐,指南基于当前标准化方法提供管理信息。
- 临床医生应根据肿瘤风险分层和患者具体临床特征确定最佳治疗方案。
研究设计与样本
- EAU UTUC指南小组系统检索Medline并综述现有UTUC指南及文献,由专家组对证据进行权重评价。
主要发现
- 60%的UTUC在诊断时已为浸润性肿瘤,因此适当的诊断最为重要。
- 根治性肾输尿管切除术后膀胱内单次灌注丝裂霉素可降低膀胱肿瘤复发风险。
- 低风险肿瘤且双肾功能良好者,保肾管理应作为首选治疗选择。
- 局部晚期UTUC根治性肾输尿管切除术后,推荐顺铂为基础的化疗。
关键数值与推荐
- 推荐采用2017年TNM分类。
- 低风险肿瘤且双肾功能良好者,保肾管理应作为首选治疗选择。
- 根治性肾输尿管切除术后,膀胱内单次灌注丝裂霉素可降低膀胱肿瘤复发风险。
- 局部晚期UTUC根治性肾输尿管切除术后,推荐顺铂为基础的化疗。
临床怎么用
- 临床医生应基于风险分层和患者具体临床特征制定个体化治疗方案。
- 对低风险且双肾功能良好的UTUC患者,优先考虑保肾管理。
- 根治性肾输尿管切除术后,可考虑膀胱内单次灌注丝裂霉素以降低膀胱复发风险。
- 局部晚期UTUC根治术后,应评估并给予顺铂为基础的化疗。
局限性
- UTUC罕见,数据不足,无法提供强推荐。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: The European Association of Urology (EAU) Guidelines Panel on Upper Urinary Tract Urothelial Carcinoma (UTUC) has prepared updated guidelines to aid clinicians in the current evidence-based management of UTUC and to incorporate recommendations into clinical practice. OBJECTIVE: To provide an overview of the EAU guidelines on UTUC as an aid to clinicians. EVIDENCE ACQUISITION: The recommendations provided in the current guidelines are based on a thorough review of available UTUC guidelines and articles identified following a systematic search of Medline. Data on urothelial malignancies and UTUC were searched using the following keywords: urinary tract cancer, urothelial carcinomas, upper urinary tract carcinoma, renal pelvis, ureter, bladder cancer, chemotherapy, ureteroscopy, nephroureterectomy, neoplasm, adjuvant treatment, instillation, recurrence, risk factors, and survival. References were weighted by a panel of experts. EVIDENCE SYNTHESIS: Owing to the rarity of UTUC, there are insufficient data to provide strong recommendations. The 2017 tumour, node, metastasis (TNM) classification is recommended. Recommendations are given for diagnosis and risk stratification as well as for radical and conservative treatment, and prognostic factors are discussed. A single postoperative dose of intravesical mitomycin after nephroureterectomy reduces the risk of bladder tumour recurrence. Kidney-sparing management should be offered as a primary treatment option to patients with low-risk tumour and two functional kidneys. After radical nephroureterectomy, cisplatin-based chemotherapy is indicated in locally advanced UTUC. CONCLUSIONS: These guidelines contain information on the management of individual patients according to a current standardised approach. Urologists should take into account the specific clinical characteristics of each patient when determining the optimal treatment regimen, based on the proposed risk stratification of these tumours. PATIENT SUMMARY: Urothelial carcinoma of the upper urinary tract is rare, but because 60% of these tumours are invasive at diagnosis, an appropriate diagnosis is most important. A number of known risk factors exist.
引用
- Rouprêt M, Babjuk M, Burger M, et al. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2020 Update. Eur Urol. 2020. PMID: 32593530. doi:10.1016/j.eururo.2020.05.042
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。